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Abstract
Familial nonmedullary thyroid cancer (NMTC) has not been clearly linked to causal 
germline variants, despite the large role that genetic factors play in risk. Recently, 
HABP2 G534E (rs7080536A) has been implicated as a causal variant in NMTC. We 
have previously shown that the HABP2 G534E variant is not associated with TC risk in 
patients from the British Isles. Hispanics are the largest and the youngest minority in 
the United States and NMTC is now the second most common malignancy in women 
from this population. In order to determine if the HABP2 G534E variant played a 
role in NMTC risk among Hispanic populations, we analyzed 281 cases and 1105 
population-matched controls from a multicenter study in Colombia, evaluating the 
association through logistic regression. We found that the HABP2 G534E variant was 
not significantly associated with NMTC risk (P = 0.843) in this Hispanic group. We also 
stratified available clinical data by multiple available clinicopathological variables 
and further analyzed the effect of HABP2 on NMTC presentation. However, we failed 
to detect associations between HABP2 G534E and NMTC risk, regardless of disease 
presentation (P ≥ 0.273 for all cases). Therefore, without any significant associations 
between the HABP2 G534E variant and NMTC risk, we conclude that the variant is not 
causal of NMTC in this Hispanic population.
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Introduction
Thyroid cancer (TC) is becoming epidemic, growing 
in incidence both nationally and internationally (1). 
Nonmedullary thyroid cancer (NMTC) makes up over 
95% of all cases, making it the most common endocrine 
malignancy (2). Among Hispanics in the United States, 
the country’s largest minority, NMTC is now the second 
most common cancer among women, accounting for 9% 
of all incident female cancer cases in this minority (3). 
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Even though NMTC is a highly familial malignancy (4), 
there has not been conclusive evidence for the discovery 
of highly penetrant NMTC genes.
Recently, two studies implicated a germline missense 
variant (G534E) in the HABP2 gene as the cause of famil-
ial NMTC (5, 6). Gara and coworkers (5) first reported 
the cosegregation of HABP2 G534E variant with either 
papillary TC (PTC) or follicular adenomas among seven 
members of the same family. The authors also demon-
strated that HABP2 G534E had a dominant-negative 
function and based on cosegregation and functional 
data concluded that HABP2 G534E was causal of NMTC 
in the family. More recently, Zhang and Xing (6) also 
concluded that HABP2 G534E was causal of NMTC. This 
conclusion was based on the presence of the variant in 
three individuals from the same family and in four addi-
tional individuals belonging to four different kindred 
out of total 29 kindred studied (6). Since then, the role 
of HABP2 G534E in NMTC has been highly contested 
given its relatively high frequency in the general popula-
tion (7, 8, 9, 10).
In order to assess the NMTC risk conferred by HABP2 
G534E, we previously carried out an association study 
using over 2000 NMTC cases and over 5000 population 
controls from the British Isles (11). We found that HABP2 
G534E was present at a relatively high frequency (4.6%) 
in the population and it was not associated with NMTC 
risk, even when the data were stratified by age of onset 
and NMTC subtypes (11). Other groups have also reported 
similar negative results in sporadic and familial PTC cases 
of European (12) and Chinese (13) ancestries. Intrigued by 
these conflicting reports on the role of HABP2 G543E in 
NMTC, we decided to analyze this variant in South Ameri-
can Hispanics, a population of admixed American Indian, 
European and African ancestries (14).
Materials and methods
Study subjects
All cases and controls were recruited in five Colombian 
cities (Bogotá, Ibagué, Neiva, Medellín and Pasto) between 
2010 and 2014 as part of a population-based multicenter 
study of thyroid cancer in the country. Ethics committees 
from the University of Tolima, Hospital Federico Lleras 
Acosta, Hospital Fernando Moncaleano, and Hospital 
Pablo Tobón Uribe approved the research protocol used 
in the study. These recruitment hospitals are tertiary 
healthcare centers in major Colombian cities, and in 
most instances, they represent the only regional centers 
offering radiation and surgical therapy for thyroid cancer. 
Given that medicine is socialized in Colombia, these 
hospitals attend patients from all socioeconomic classes 
in the country. Thus, these cases recruited in the study 
are representative of the general Colombian population. 
In total, 281 histologically verified NMTC cases (48 males 
and 233 females) and 1105 population-matched controls 
were included in the study. All controls were recruited at 
the same hospitals, were cancer-free and older than 50 
years at the time of recruitment. The mean age of cases 
was 46.89 years (s.d. = 1.66) and mean age of controls 
was 64.15 years (s.d. = 0.59). Clinical data such as age of 
onset, NMTC subtype, family history of cancer, presence 
or absence of local or distal metastasis, and histological 
characteristics such as vascular and capsule invasion, 
focality, and bilaterality were available for most of the 
cases (n = 241).
Genotyping
Genomic DNA was isolated from whole blood samples using 
Promega Maxwell 16 system (Promega). HABP2 G534E 
variant was genotyped using competitive allele-specific 
KASP genotyping chemistry (LGC Genomics, Teddington, 
UK) as described previously (11). The genotyping call 
rates were >98%, with controls derived from replicates 
with verified genotypes used in all assays. Four additional 
markers, two upstream of G534E (rs10787491, rs932650) 
and two downstream of G534E (rs10885478, rs1885434), 
were genotyped in five G534E heterozygous individuals 
for haplotype analysis.
Statistical analysis
All genotype frequencies and association testing using 
logistic regression models were performed using PLINK 
(15). Genotypes were in Hardy–Weinberg equilibrium.
Results
Association between HABP2 G534E and TC risk in 
Hispanic population
In this study, we genotyped the HABP2 G534E variant in 
281 NMTC cases and 1105 population- and sex-matched 
controls from Colombia. We found that HABP2 G534E 
was polymorphic in both cases (frequency = 1.4%) and 
controls (frequency = 1.3%). All heterozygous carrier 
controls were >50 years. The mean age of heterozygous 
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carrier cases was 43.57 years (s.d. = 16.066) and the age of 
heterozygous carrier controls was 65.44 years (s.d. = 4.33). 
Consistent with the similar frequency of these variants 
in cases and controls, we failed to detect an association 
between HABP2 G534E and NMTC risk in our Hispanic 
case–control study (odds ratio, OR = 0.92, 95% confidence 
interval, CI: 0.4–2.11, P = 0.843).
Association between HABP2 G534E and TC risk in 
cases stratified by clinical variables
We further looked into any possible association between 
HABP2 G534E and NMTC risk by stratifying the cases 
by clinical variables. As shown in Table  1, the variant 
was not significantly associated with early (<45 years) 
or late (≥45 years) disease onset, presence or absence 
of family history of cancer, or with any other tumor 
histological feature (size, focality, capsular invasion, 
vascular invasion, lymph node metastasis or extrathyroid 
extension).
The frequency of the HABP2 G534E allele varies 
across population of different ancestries (11). This 
variant is absent from African and East Asian populations 
but is present at ~5% frequency in populations of 
European ancestry (11). Colombians are a population 
of mixed European, Amerindian and African ancestries, 
where genetic ancestry correlates with geographical 
origin and socioeconomic status (SES) (14, 16, 17, 
18). To account for a potentially confounding role of 
geographical origin and SES, we carried out analyses that 
incorporated recruitment center and SES. We failed to 
detect an association between HABP2 G534E and TC risk 
even when these covariates were incorporated into the 
analyses (P = 0.60, data not shown).
Haplotype analysis
We also investigated the haplotype surrounding HABP2 
G534E to test the possibility of different origins of G534E 
allele, using previously described methods (11) in five 
cases who were HABP2 G534E heterozygous. These five 
individuals shared the same haplotype that we previously 
identified in the British Isles (11), suggesting a European 
ancestry of this variant in Hispanics (data not shown).
Table 1 Association between HABP2 G534E and different clinical variables.
Variable
HABP2 genotype
G534E frequency OR (95% CI)*Heterozygous Wild type
Age at diagnosis
≥45 4 (2.4) 165 (97.6) 169 (0.012) 0.87 (0.3–2.49)
<45 3 (2.7) 108 (97.3) 111 (0.014) 1 (0.3–3.29)
Family history of cancer*
Present 3 (3.4) 84 (96.6) 87 (0.017) 1.28 (0.39–4.22)
Absent 4 (2.1) 189 (97.9) 193 (0.01) 0.76 (0.27–2.17)
Histologic type
FTC 4 (3.7) 105 (96.3) 109 (0.018) 1.36 (0.47–3.89)
PTC 3 (1.8) 168 (98.2) 171 (0.009) 0.64 (0.2–2.12)
Tumor size
Small <2 cm 5 (3.7) 131 (96.3) 136 (0.018) 1.36 (0.52–3.54)
Large ≥2 cm 2 (1.9) 102 (98.1) 104 (0.01) 0.71 (0.17–2.97)
Focality
Multifocal 4 (4.5) 85 (95.5) 89 (0.022) 1.67 (0.58–4.8)
Unifocal 3 (2) 148 (98) 151 (0.01) 0.73 (0.22–2.42)
Capsular invasion
Absent 3 (2.2) 133 (97.8) 136 (0.011) 0.81 (0.25–2.67)
Present 4 (3.8) 100 (96.2) 104 (0.019) 1.43 (0.5–4.08)
Vascular invasion
Absent 6 (3.2) 182 (96.8) 188 (0.016) 1.18 (0.49–2.85)
Present 1 (1.9) 51 (98.1) 52 (0.01) 0.71 (0.1–5.22)
Lymph node metastasis
Absent 5 (3) 161 (97) 166 (0.015) 1.11 (0.43–2.88)
Present 2 (2.7) 72 (97.3) 74 (0.014) 1 (0.24–4.21)
Extrathyroid extension
Absent 6 (3) 194 (97) 200 (0.015) 1.11 (0.46–2.68)
Present 1 (2.5) 39 (97.5) 40 (0.013) 0.92 (0.12–6.83)
*None of the variables were found to be statistically significant (all two-sided P values ≥0.273).
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Discussion
In this study, we tested the association between HABP2 
G534E and NMTC in a Hispanic population-based study 
using SNP genotyping and logistic regression methods. 
We also investigated the associations between this variant 
and disease manifestation. We did so as recent reports 
have suggested conflicting results about the role of 
HABP2 G534E and NMTC risk. Here, we failed to detect 
an association between HABP2 G534E and NMTC risk in 
our Hispanic population-based study.
NMTC is the second most common malignancy in 
the Hispanic population and there is an urgent need for 
effective clinical management of this common endocrine 
malignancy. Considering that around 45% of male 
and 60% of female NMTC cases can be attributed to 
over-diagnosis (19), it is becoming extremely important 
to develop better risk stratification tools that can guide 
aggressive or conservative treatment of this cancer. On 
this background, finding novel genetic variants that truly 
increase the risk of NMTC will be very beneficial. HABP2 
G534E is a low- to moderate-frequency variant that occurs 
in 2–6% of the population. Here, consistent with previous 
studies in European and Chinese populations, we failed to 
replicate association between HABP2 G534E and TC risk in 
Hispanic population as well. We, however, acknowledge 
that our study may have limited power to detect the low-
penetrance effect of a variant that is relatively rare in the 
population and that future studies, using larger sample 
sizes, will be required. However, our data indicate that 
HABP2 G534E is unlikely to be causal (i.e. a moderate- to 
high-penetrance effect) to NMTC in populations of diverse 
ethnicity, and caution should be taken in interpreting TC 
causality associated with this common variant.
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